+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and tolerability of Mocertatug Rezetecan in adults with advanced solid tumors, including platinum-resistant ovarian cancer and endometrial cancer. The study aims to observe how levels of Mocertatug Rezetecan change over time at different doses. Participants have tumors that have not responded to or cannot tolerate standard treatments. The study includes two parts dose escalation and dose expansion, both involving administration of Mocertatug Rezetecan as an injection. Participants receive varying doses to determine safety, tolerability, and clinical activity. Tissue samples will be collected for biomarker analysis, including expression of B7-H4. The study may last up to approximately 31 months depending on the part and participant response. Participants will undergo regular assessments including evaluation of tumor response using standard criteria, monitoring of blood and urine tests, vital signs, ECGs, and other laboratory measures. Safety is closely monitored through tracking adverse events and specific toxicity markers. The main outcomes measured include dose limiting toxicities in the first 21 days and objective response rates over about 28 months. Follow-up evaluations continue for safety and clinical activity throughout the study.

Age: 18Years +All GendersPhase 1
65 locations
E

Actively Recruiting

Researchers are studying a treatment for adults with muscle-invasive bladder cancer, a condition where cancer has spread into the muscle wall of the bladder. The usual approach involves chemotherapy followed by bladder removal surgery, which can cause significant long-term changes. This study focuses on using a combination of enfortumab vedotin and pembrolizumab to help people keep their bladder, especially for those who respond well to this therapy and wish to avoid surgery. Participants will receive infusions of enfortumab vedotin on the 1st and 8th days of every 3-week cycle, along with pembrolizumab on the 1st day of each cycle. Treatment continues unless the cancer worsens, does not improve after 9 cycles, or if other medical reasons arise. Those whose cancer does not respond may need surgery, radiotherapy, or chemotherapy. The study monitors safety and tumor status regularly during these cycles. Throughout the study, participants will have safety checks at each visit, tumor assessments at some visits, and medical monitoring. After stopping treatment, health checks and scans occur every 3 months for 2 years, then every 6 months for up to 5 years if the cancer remains stable. Once cancer progresses, scans stop, but telephone health checks continue every 3 months. The main outcomes measured are the rate of complete response to treatment and the duration participants keep their bladder intact over two years.

Age: 18Years +All GendersPhase 2
68 locations
F

Actively Recruiting

Researchers are studying AVZO-021, an oral medication that inhibits cyclin-dependent kinase 2 CDK2, in patients with advanced solid tumors. This Phase 12, first-in-human, open-label, nonrandomized trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021. The study focuses on tumors including HRHER2- breast cancer and CCNE1 altered malignancies, where standard treatments may no longer be effective or safe. Participants receive escalating doses of AVZO-021 once daily in 28-day cycles as monotherapy or in combination with other cancer therapies such as fulvestrant, palbociclib, ribociclib, abemaciclib, sacituzumab govitecan-hziy, or carboplatin. The study includes a dose-escalation phase to determine the recommended phase 2 dose and a dose-expansion phase to assess antitumor activity. Different cohorts receive AVZO-021 alone or combined with these agents depending on their cancer type and treatment history. During the study, participants undergo regular evaluations including monitoring for dose-limiting toxicities and treatment-emergent adverse events. Pharmacokinetic assessments are performed during the first cycle to measure drug concentration and metabolism. Researchers measure tumor response, progression-free survival, overall survival, and duration of response. Safety and laboratory tests are conducted throughout the study. Participation may last several months or longer depending on treatment response and tolerability.

Age: 18Years +All GendersPhase 1Phase 2
13 locations
R

Actively Recruiting

Researchers are evaluating whether casdatifan combined with cabozantinib can improve progression-free survival compared to placebo plus cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma. The study focuses on patients who have previously received anti-PD-1 or anti-PD-L1 therapies in their most recent treatment, with no more than one prior metastatic treatment regimen. This is a randomized, double-blind, active-controlled phase 3 trial aimed at advancing treatment options for this patient group. Participants will be randomly assigned to receive either casdatifan and cabozantinib or placebo and cabozantinib, both taken orally. The study includes two treatment arms one experimental arm with casdatifan and cabozantinib, and a comparator arm with placebo and cabozantinib. Treatment is ongoing, with monitoring for up to approximately 33 months for key outcomes, and follow-up for overall survival up to about 64 months. Throughout the study, participants will undergo regular assessments including imaging scans evaluated by a blinded independent review to measure tumor response and progression. Researchers will track progression-free survival, overall survival, response rates, duration of response, disease control, and treatment-related adverse events. Symptom changes will also be monitored using patient-reported measures. The total participation duration may extend up to several years to capture long-term outcomes and safety data.

Age: 18Years +All GendersPhase 3
191 locations